Concepedia

Author

Giovanni Randon

Fondazione IRCCS Istituto Nazionale dei TumoriORCID

Also Known As

Camilla Damonte, G. Randon, GIOVANNI RANDON, Giovanni Randon, Hassan Ashktorab

200

Publications

2.6K

Citations

28

H-Index

49

Concepts

All Affiliations

Fondazione IRCCS Istituto Nazionale dei TumoriIstituto Oncologico VenetoIstituti di Ricovero e Cura a Carattere ScientificoAzienda Ospedaliera Universitaria PisanaUniversity of Pisa
GR

About

Giovanni Randon is an author at Fondazione IRCCS Istituto Nazionale dei Tumori specializing in medicine, oncology, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

16

21

944

2

Health Sciences

3

3

85

3

Gastroenterology

3

3

158

4

Biostatistics

1

1

32

5

Cell Biology

1

1

68

Giovanni Randon

×

51

Publications

2.2K

Citations

28

H-Index

YearCitations

Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma

Alice Indini, Lorenza Di Guardo, Carolina Cimminiello,

Journal of Cancer Research and Clinical Oncology

2018

193

Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials

Filippo Pietrantonio, Giovanni Randon, Maria Di Bartolomeo,

ESMO Open

2021

186

Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O<sup>6</sup>-Methylguanine–DNA Methyltransferase–Silenced Metastatic Colorectal Cancer: The MAYA Trial

Federica Morano, Alessandra Raimondi, Filippo Pagani,

Journal of Clinical Oncology

2022

120

Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers

Giovanni Fucà, Romain Cohen, Sara Lonardi,

Journal for ImmunoTherapy of Cancer

2022

107

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer

Élena Elez, Javier Ros, J. Fernández,

Nature Medicine

2022

103

INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC).

Filippo Pietrantonio, Alessandra Raimondi, Sara Lonardi,

Journal of Clinical Oncology

2023

90

EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort

Arsela Prelaj, Roberto Ferrara, Sara Elena Rebuzzi,

Cancers

2019

77

Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO

Daniele Rossini, Carlotta Antoniotti, Sara Lonardi,

Journal of Clinical Oncology

2022

71

KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population

Marta Schirripa, Floriana Nappo, Chiara Cremolini,

Clinical Colorectal Cancer

2020

68

Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): The AVANA study.

Lisa Salvatore, Maria Bensi, Salvatore Corallo,

Journal of Clinical Oncology

2021

64

Page 1